Guard Therapeutics
18.5 SEK -1.07%Be the first to follow this company
Guard Therapeutics is a developer of pharmaceuticals in the field of oxidative stress. The company focuses primarily on the research, development, and commercialization of pharmaceuticals that are intended to prevent the occurrence and complications of acute kidney damage. In preclinical studies, pharmaceuticals have been shown to protect exposed tissue and support regenerative processes. Treatment of acute kidney injuries in conjunction with heart surgery is a priority in clinical development.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GUARD
Daily low / high price
17.6 / 18.8
SEK
Market cap
186.14M SEK
Turnover
84.89K SEK
Volume
4.7K
Financial calendar
General meeting
2024-05-08
Interim report
2024-05-08
Interim report
2024-08-22
Interim report
2024-11-13
Annual report
2025-02-20
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Jan Ståhlberg | 16.4 % | 16.4 % |
M2 Asset Management AB | 11.0 % | 11.0 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Guard Therapeutics offentliggör bokslutskommuniké för 2023
Guard Therapeutics presenterade utvecklingsstrategi och nya prekliniska resultat på R&D Update
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools